GENENTECH, INC for GENENTECH INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 19, 2019 | $1,610,000 | Replaced |
| 2nd Quarter - Amendment | Sep 29, 2021 | $1,620,000 | Yes |
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Financial Institutions/Investments/Securities FIN
- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE LYTTON PHILLIPS | — |
Copyright/Patent/Trademark CPT
S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Pharmacy PHA
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Medical/Disease Research/Clinical Labs MED
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Taxation/Internal Revenue Code TAX
H.R.1, Tax Reform Act of 2017 (Public Law No. 115-97) H.R.88, Retirement, Savings, and Other Tax Relief Act of 2018 and Taxpayer First Act of - Issues related to the tax reform bill and implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
Foreign Relations FOR
Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE LYTTON PHILLIPS | — |
| ANDREW WESLEY WOMACK | — |
Health Issues HCR
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Medicare/Medicaid MMM
S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT New | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY New | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Budget/Appropriations BUD
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| VANESSA GANNON BURT | — |
| ELISE MARIE CONNER | — |
| BRIAN MALONEY | — |
| CATHERINE LYTTON PHILLIPS | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.